6JUNE 2024TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comFrom cancer vaccines and antibodies to the cytokine therapies and oncolytic viruses, the field of immunotherapy is rapidly advancing, providing answers to the age-old question of whether cancer can be cured. This progress is echoed through scientific development supported by extensive research and pharmaceutical space that boost its efficacy. One of the recent trends in the field is T cell engagers, engineered to activate an immune response against cancer. These therapeutic molecules are designed to bind to a target antigen expressed on a cancer cell and to a trigger molecule on T cells, such as CD3. They then engage T cells that are present in tumours but not capable of recognising cancer cells, redirecting their activity toward the tumour. Another interesting therapy is antibody drug conjugates (ADCs), which are targeted medicines that deliver chemotherapy agents to cancer cells. ADCs deliver the chemotherapy via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. After binding to the target (cancer protein or receptor), the ADC releases a cytotoxic drug into the cancer cell, damaging its DNA or preventing new cancer cells from forming and spreading.Based on the promise of these benefits, the global immunotherapy drug market is projected to grow at a CAGR of 6.93 percent during the forecast period from 2024 to 2032.This edition of Pharma Tech Outlook brings insights into the latest developments in the immunotherapy that are shaping the future of cancer treatments. It features a thought leadership article from Cheryl Grove Cox, Cell Therapy Operations Director, Moffitt Cancer Center, who share insights on how cell therapy is a game-changing approach to medicine, offering the potential to restore health by repairing and replacing damaged cells and tissues. It also features an article from Simon Davies, Executive Director of Teen Cancer America, who sheds light on the nuclear medicine imaging procedures are incredibly valuable in diagnosing cancers and determine the optimal course of treatment for each patient, and then measure their effectiveness.This edition also brings you the story of the top immunotherapy solution providers. One of the them is CROSSIGNAL Therapeutics, specializing in developing new generation of small molecule anti-cancer immunotherapy, followed by Inimmune, offering innovative therapies by harnessing the innate immune system. In this edition featuring the Top Immunotherapy Solutions Providers 2024, we hope you find the right assistance in choosing the best immunotherapy companies suited for your needs. Let us know your thoughts!The Rise of New Chapter in Cancer Immunotherapy Copyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.JUNE - 24 - 2024, Vol 10 - Issue 07 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Parley MeadowTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >